CHICAGO — Two retrospective studies presented at the annual meeting of the American Society of Clinical Oncology show that changes in hormone- and HER2-receptor status are indeed possible between primary and recurrent breast cancer lesions, and that survival outcomes are severely compromised when they occur.
PREVIEW